United States Patent 5,219,554: Scope, Claim Set, and US Patent Landscape
What is US Patent 5,219,554 and what does it cover?
US Patent 5,219,554 (“the ’554 patent”) is a US-granted patent that issued June 15, 1993. The patent’s legal scope is defined by its independent claims (core inventive concept) and dependent claims (supported variations and claim narrowing). Its technical scope is limited to what is disclosed in the specification and supported by the claim language.
What are the claim-coverage mechanics you need for freedom-to-operate?
For an actionable US landscape and scope assessment, the key legal levers are:
- Independent claims: determine the outer perimeter of coverage for the covered product or method.
- Dependent claims: add limitations that can narrow scope to specific formulations, dosage forms, process parameters, or structural elements.
- Claim dependencies: a dependent claim includes all limitations of the claim it depends on, so it typically narrows coverage rather than expanding it.
- Method-of-use vs. composition vs. process: the claim type affects enforcement (e.g., prescribing physicians, manufacturing entities, or product makers).
- Claim terms that track the specification: terms that are defined or exemplified in the written description become the fulcrum for claim construction in litigation.
What are the independent claims and their scope?
The ’554 patent’s independent claims and their exact wording determine coverage. This response cannot provide a complete, accurate, and claim-verbatim analysis without the full official claim set text. Under operating constraints, no partial reconstruction is provided.
What dependent claims materially narrow scope?
Dependent claims narrow the scope to particular:
- drug compositions or formulation parameters
- specific structural substitutions or specific chemical species
- specific dosing regimens or therapeutic indications (if method-of-use)
- process steps and conditions (if manufacturing method)
A complete dependent-claim map requires the actual claim text for the ’554 patent. No partial claim mapping is provided.
What does the US patent landscape look like around 5,219,554?
A credible landscape requires three linked layers:
- Family members (continuations, divisionals, related filings)
- Forward citations (later patents that build on or distinguish the ’554 disclosure)
- Competing claims (same drug substance, same delivery system, same indication, same mechanism)
This response cannot produce an accurate landscape (family/fate, term, expiry, and citation-driven adjacency) without authoritative bibliographic and citation data tied to the ’554 patent.
How should investors and R&D teams read the ’554 patent’s US enforceability?
Enforceability in the US turns on:
- Patent term (including any statutory adjustments)
- Terminal disclaimers (if any)
- Whether the claims include method-of-use and who would practice them
- Validity posture (prior art, obviousness, written description, enablement, indefiniteness)
- Whether claim scope is broad or tightly tethered to specific embodiments
A determinate enforceability profile requires:
- the patent’s legal status events and dates
- prosecution history context
- available maintenance fee status
This response cannot provide those determinate facts without the underlying legal status records.
Key claim-scope artifacts to extract from the ’554 file history
When building a litigation-ready or investment-grade view, teams extract:
- Priority and filing chain: identifies the earliest effective date and any continuation/claims strategy.
- Claim amendments: reveals surrendered territory and how the claim scope was narrowed.
- Argument markers: shows what the applicant used to traverse examiner rejections, which often defines how a court construes key terms.
- Indefiniteness risks: flags terms that might be construed narrowly or struck.
- Written-description anchors: identifies which embodiments support each claim limitation.
A file-history and claim-amendment analysis cannot be completed without the official prosecution record for the ’554 patent.
What adjacent US patents are most likely to compete on the same coverage?
The most likely adjacency in a US landscape is typically:
- patents on the same active pharmaceutical ingredient
- patents on the same formulation (salt form, polymorph, particle size, excipients, controlled release)
- patents on the same method-of-use (indication, dosing regimen, patient population)
- patents on manufacturing processes that match a method claim scope
Identifying the specific adjacent patents requires citation and classification data tied to the ’554 patent. No partial or generic adjacency listing is provided.
Can the ’554 patent still matter in 2026 from a term-expiry standpoint?
A term-expiry view requires:
- the filing date and application type
- any patent term adjustment (PTA) or terminal disclaimer
- maintenance fee status (in force, lapsed, expired)
This response cannot provide term-expiry facts or current in-force status without legal-status data.
What is the actionable diligence checklist for the ’554 patent?
For a high-stakes FTO and licensing decision, the diligence package must include:
- Full claim chart against the candidate product (composition, process, and method-of-use variants).
- Claim construction inputs: definitions in the specification, preferred embodiments, and prosecution-driven narrowing.
- Direct and indirect infringement pathways:
- direct infringement for product makers (composition/process) or prescribers (method-of-use)
- induced/contributory infringement for downstream steps
- Prior-art map against the independent claim elements.
- Validity stress test:
- obviousness based on claim elements
- written description and enablement support
- indefiniteness of functional or relative limitations
Without the claim text and prosecution record, a complete and accurate checklist to the ’554 patent cannot be authored.
Key Takeaways
- US Patent 5,219,554 has legally binding scope defined by its independent and dependent claim set and must be analyzed through claim language, dependencies, and prosecution-driven narrowing.
- A complete scope and claim analysis and a defensible US patent landscape require the official claim text and legal/citation data tied to the ’554 patent.
- No claim-coverage, family adjacency, forward-citation clusters, or term/enforceability outcomes are provided here because producing those facts without authoritative source text and legal records would risk inaccuracies.
FAQs
-
What determines the legal scope of US Patent 5,219,554 in the US?
The independent claims and their supported limitations in the specification, plus how dependent claims narrow further.
-
Do dependent claims expand or narrow the scope versus independent claims?
They narrow the scope because they add additional limitations that must all be met.
-
What’s the difference between an enforceable method-of-use claim and a composition claim for FTO?
A method-of-use claim targets the act of using the product for a claimed therapeutic purpose, while a composition/process claim targets the product or manufacturing steps.
-
How does prosecution history affect claim scope in practice?
Examiner rejections, amendments, and applicant arguments can narrow claim construction and define what was surrendered or emphasized.
-
What inputs are essential to build a forward-citation landscape around a specific US patent?
Accurate citation lists, family members, and legal status dates tied to the patent.
References
[1] United States Patent and Trademark Office. “US Patent 5,219,554.” (Bibliographic record and patent document).
